On the Horizon: New Diabetes Drugs and Devices Under Investigation
Research news from the American Diabetes Association 72nd Scientific Sessions
June 8–12, 2012 | Philadelphia, Pennsylvania
NOTE: These products are not currently approved by the Food and Drug Administration.
DiaPep277, a molecule that alters the immune system, slowed the decline of insulin-producing beta cells in people with newly diagnosed type 1 diabetes.
EndoBarrier is an intestinal liner that is designed to mimic gastric bypass, but without the surgery. People with type 2 lost weight and lowered their blood glucose after six months with the device.
This potential type 1 drug is a long-lasting version of C-peptide, a protein that is secreted by the pancreas along with insulin, but is in short supply in people with type 1. This medication is being developed to treat nerve problems in the arms, hands, legs, and feet (peripheral neuropathy).
Researchers reported preliminary progress on two types of long-acting insulin in development. Insulin degludec was associated with less hypoglycemia than insulin glargine (Lantus) in people with type 2. An insulin known as LY2605541 was also associated with less hypoglycemia than glargine, and it promoted minor weight loss.
This hormone that raises blood glucose levels could safeguard users of insulin pumps against hypoglycemia. However, the standard formulation is created by mixing a powder and a liquid right before use, and rapidly loses potency. Researchers found they could stabilize the solution by increasing pH, allowing it to be pumped.
SGLT2 inhibitors are a novel class of type 2 medications that increase the amount of glucose excreted in urine. Canagliflozin lowered A1C more than sitagliptin (Januvia) in a yearlong trial. Dapagliflozin was found to decrease body weight and blood glucose levels through a common mechanism. Empagliflozin, used with metformin or alone, was shown to lower body weight and blood glucose in a 78-week study.